Featuring Dr. Jesse Boehm
Show Notes:
In this episode, Dr Jesse Boehm relates his inspiring journey into the world of translational research. Dr Boehm focuses on how his laboratory engineered solutions to complex biological problems, particularly cancer. He stresses the importance of working alongside cancer patients, sharing a very personal story and the impact it had on his perspective. Thanks to this perspective, Dr. Boehm encourages cancer scientists to consider urgency and patient impact of their research.
Guest:
Jesse Boehm, PhD
Chief Science Officer, Break Through Cancer
Jesse Boehm is the Chief Science Officer of Break Through Cancer and maintains a research lab focused on bringing the power of functional genomics to bear on living samples from cancer patients with particular emphasis on rare and underrepresented tumors. Before joining Break Through Cancer, Jesse spent 14 years in the Broad Institute’s Cancer Program, most recently as an Institute Scientist and Scientific Director of the Cancer Dependency Map project. As the Director of the Broad’s Cancer Model Development Center (part of the National Cancer Institute’s Human Cancer Models Initiative), he led his laboratory in developing a scalable capacity to convert patient tumors into organoids and other cell models. Prior, he was the recipient of a Broad Institute Merkin Fellowship and the Associate Director of the Broad’s Cancer Program. In these leadership roles, he drove the scientific planning and strategic execution of a diverse set of program projects, collaborations, and activities for over a decade. Jesse received his BS in biology from MIT and his PhD from Harvard University, Division of Medical Sciences at Dana-Farber Cancer Institute.
Host:
David Yarmosh, MS
Lead Bioinformatician, ATCC
David Yarmosh is a lead bioinformatician in ATCC’s Sequencing and Bioinformatics Center. He’s a graduate of New York University’s Tandon School of Engineering. He has been working in large data aggregation and analysis since 2013 and microbial genomics with a focus on biosurveillance R&D efforts since 2016. David has led international training exercises in Peru and Senegal, sharing metagenomic analytical capabilities. His interests include genomics database construction, metadata collection, drug resistance mechanisms, bioinformatics standards, and machine learning. Since joining ATCC in 2020, David has worked extensively in SARS-CoV-2 classification, epidemiology, and genomics evaluation, including enhanced and uniform variant reporting. He has contributed more broadly to genomics reporting and analytical standardization and he has helped develop the podcast Behind the Biology, which he now hosts.
Advanced cell models
ATCC Organoids
ATCC provides organoids isolated from multiple organs including colon, small intestine, stomach, breast, esophagus, lung, liver, prostate, and pancreas. Discover their advantages over existing cancer models.
HCMI Cancer Models
We are continually adding 2-D and 3-D patient-derived cancer models to our portfolio. These next-generation models include both common as well as rare and understudied examples of cancer from numerous tissues.